Immunosuppression: Rheumatoid Arthritis and Transplants Flashcards
BIOLOGICS
a. Etanercept
b. Adalimumab
c. Infliximab
d. Sulfasalazine
e. Azathioprine/ Mercaptopurine
f. Tacrolimus
g. Cyclosporine
h. Mycophenolate
a. Etanercept
b. Adalimumab
c. Infliximab
TRADITIONAL
a. Etanercept
b. Adalimumab
c. Infliximab
d. Sulfasalazine
e. Azathioprine/ Mercaptopurine
f. Tacrolimus
g. Cyclosporine
h. Mycophenolate
d. Sulfasalazine
e. Azathioprine/ Mercaptopurine
Immunosuppressant’s
f. Tacrolimus
g. Cyclosporine
h. Mycophenolate
f. Tacrolimus
g. Cyclosporine
h. Mycophenolate
MECHANISM OF ACTION: ◦Has two receptors which target and bind to TNF (Tumor Necrosis Factor) and neutralizes it a. Etanercept b. Adalimumab c. Infliximab d. Sulfasalazine e. Azathioprine/ Mercaptopurine f. Tacrolimus g. Cyclosporine h. Mycophenolate
a. Etanercept
ADVERSE EFFECTS: ◦Injection site reactions (37% of patients may experience) ◦ Itching, erythema, swelling, pain ◦ Subcutaneous (once weekly) a. Etanercept b. Adalimumab c. Infliximab d. Sulfasalazine e. Azathioprine/ Mercaptopurine f. Tacrolimus g. Cyclosporine h. Mycophenolate
a. Etanercept
NURSING CONSIDERATION: ◦ Monitor the site for redness, pain and swelling after administration ◦ Report if doesn’t improve after a few days a. Etanercept b. Adalimumab c. Infliximab d. Sulfasalazine e. Azathioprine/ Mercaptopurine f. Tacrolimus g. Cyclosporine h. Mycophenolate
a. Etanercept
b. Adalimumab
ADVERSE EFFECTS: ◦ Serious Infections (this drug suppresses the immune system!) ◦ Higher risk for Fungal infections, Atypical bacteria (such as TB!) ◦ Legionella pneumophila, Mycobacterium tuberculosis a. Etanercept b. Adalimumab c. Infliximab d. Sulfasalazine e. Azathioprine/ Mercaptopurine f. Tacrolimus g. Cyclosporine h. Mycophenolate
a. Etanercept
b. Adalimumab
c. Infliximab
◦ Don’t forget TNF is part of our defense system
a. Etanercept
b. Adalimumab
c. Infliximab
d. Sulfasalazine
e. Azathioprine/ Mercaptopurine
f. Tacrolimus
g. Cyclosporine
h. Mycophenolate
ok
TNF ◦ Higher risk for Fungal infections, Atypical bacteria (such as ?)
a. Etanercept
b. Adalimumab
c. Infliximab
d. Sulfasalazine
e. Azathioprine/ Mercaptopurine
f. Tacrolimus
g. Cyclosporine
h. Mycophenolate
TB
b. Adalimumab
c. Infliximab
◦ RISK FOR SERIOUS INFECTIONS- ◦ TB, HBV, bacterial, fungal, viral, you name it. ◦ ? + Steroids, or ? + Methotrexate a. Etanercept b. Adalimumab c. Infliximab d. Sulfasalazine e. Azathioprine/ Mercaptopurine f. Tacrolimus g. Cyclosporine h. Mycophenolate
Etanercept
b. Adalimumab
c. Infliximab
◦One of the requirements when using this medication is to check for latent TB and HBV. It is possible that use of this medication may REACTIVATE TB! a. Etanercept b. Adalimumab c. Infliximab d. Sulfasalazine e. Azathioprine/ Mercaptopurine f. Tacrolimus g. Cyclosporine h. Mycophenolate
a. Etanercept
b. Adalimumab
c. Infliximab
◦ MALIGNANCIES ◦ We have seen lymphomas and other malignancies develop during use of this medication a. Etanercept b. Adalimumab c. Infliximab d. Sulfasalazine e. Azathioprine/ Mercaptopurine f. Tacrolimus g. Cyclosporine h. Mycophenolate
a. Etanercept
b. Adalimumab
c. Infliximab
NURSING CONSIDERATIONS: ◦ Assess for s/s of malignancy (splenomegaly, hepatomegaly, night sweats, weight loss, persistent fever) a. Etanercept b. Adalimumab c. Infliximab d. Sulfasalazine e. Azathioprine/ Mercaptopurine f. Tacrolimus g. Cyclosporine h. Mycophenolate
a. Etanercept
b. Adalimumab
c. Infliximab
ADVERSE EFFECTS: ◦ Heart Failure a. Etanercept b. Adalimumab c. Infliximab d. Sulfasalazine e. Azathioprine/ Mercaptopurine f. Tacrolimus g. Cyclosporine h. Mycophenolate
a. Etanercept
b. Adalimumab
c. Infliximab
NURSING CONSIDERATIONS: ◦ Periodic monitoring ◦ Heart (Heart Failure) ◦ Liver (Hepatotoxicity) ◦ CBC (pancytopenia) a. Etanercept b. Adalimumab c. Infliximab d. Sulfasalazine e. Azathioprine/ Mercaptopurine f. Tacrolimus g. Cyclosporine h. Mycophenolate
a. Etanercept
b. Adalimumab
c. Infliximab
Don’t forget the infection risk ◦ Watch out with additive effects of immunosuppressant's ◦ No LIVE vaccines with steroid ◦ Baseline screening for TB and HBV ◦ Do NOT give in malignancies! a. Etanercept b. Adalimumab c. Infliximab d. Sulfasalazine e. Azathioprine/ Mercaptopurine f. Tacrolimus g. Cyclosporine h. Mycophenolate
a. Etanercept
b. Adalimumab
c. Infliximab
ADVERSE EFFECTS Injection Site reaction Immunosuppression Malignancy risk a. Etanercept b. Adalimumab c. Infliximab d. Sulfasalazine e. Azathioprine/ Mercaptopurine f. Tacrolimus g. Cyclosporine h. Mycophenolate
a. Etanercept
b. Adalimumab
c. Infliximab
USED TO TREAT: ◦Rheumatoid Arthritis a. Etanercept b. Adalimumab c. Infliximab d. Sulfasalazine e. Azathioprine/ Mercaptopurine f. Tacrolimus g. Cyclosporine h. Mycophenolate
a. Etanercept
USED TO TREAT: ◦Rheumatoid Arthritis ◦Crohn’s ◦Ulcerative Colitis a. Etanercept b. Adalimumab c. Infliximab d. Sulfasalazine e. Azathioprine/ Mercaptopurine f. Tacrolimus g. Cyclosporine h. Mycophenolate
b. Adalimumab
MECHANISM OF ACTION: ◦Monoclonal Antibody that targets TNF of the immune system a. Etanercept b. Adalimumab c. Infliximab d. Sulfasalazine e. Azathioprine/ Mercaptopurine f. Tacrolimus g. Cyclosporine h. Mycophenolate
c. Infliximab
b. Adalimumab
BIOLOGICS: BICYCLE Blood Dyscrasias Infection Cardiac (heart failure) Yucky (injection site) Cancer Liver Educate about SJS/TEN a. Etanercept b. Adalimumab c. Infliximab d. Sulfasalazine e. Azathioprine/ Mercaptopurine f. Tacrolimus g. Cyclosporine h. Mycophenolate
a. Etanercept
b. Adalimumab
c. Infliximab
BIOLOGICS: BICYCLE a. Etanercept b. Adalimumab c. Infliximab B? I? C? Y? C? L? E?
Blood Dyscrasias Infection Cardiac (heart failure) Yucky (injection site) Cancer Liver Educate about SJS/TEN
? is given intravenously (IVPB), can see infusion reactions (flu-like, chills, headache, fever), rarely anaphylaxis a. Etanercept b. Adalimumab c. Infliximab
c. Infliximab
? is also given subcutaneously (like Etanercept), so watch out for local reactions (20% of patients) a. Etanercept b. Adalimumab c. Infliximab
b. Adalimumab
TRADITIONAL DMARD Agents
a. Etanercept
b. Adalimumab
c. Infliximab
d. Sulfasalazine
e. Azathioprine/ Mercaptopurine
f. Tacrolimus
g. Cyclosporine
h. Mycophenolate
i. Hydroxychloroquine
d. Sulfasalazine
e. Azathioprine/ Mercaptopurine
USED TO TREAT Malaria Rheumatoid Arthritis a. Etanercept b. Adalimumab c. Infliximab d. Sulfasalazine e. Azathioprine/ Mercaptopurine f. Tacrolimus g. Cyclosporine h. Mycophenolate i. Hydroxychloroquine
i. Hydroxychloroquine
ADVERSE EFFECTS Retinal damage QT Prolongation a. Etanercept b. Adalimumab c. Infliximab d. Sulfasalazine e. Azathioprine/ Mercaptopurine f. Tacrolimus g. Cyclosporine h. Mycophenolate i. Hydroxychloroquine
i. Hydroxychloroquine
5- ASA A Bowel (treats IBD) Arthritis (Rheumatoid Arthritis) Aplastic anemia AST ALT Sulfa allergy, SUN sensitivity, SJS Aspirin like- Reye Syndrome a. Etanercept b. Adalimumab c. Infliximab d. Sulfasalazine e. Azathioprine/ Mercaptopurine f. Tacrolimus g. Cyclosporine h. Mycophenolate i. Hydroxychloroquine
d. Sulfasalazine
d. Sulfasalazine 5- ASA A ? A? A? A? A? S? A?
5- ASA A Bowel (treats IBD) Arthritis (Rheumatoid Arthritis) Aplastic anemia AST ALT Sulfa allergy, SUN sensitivity, SJS Aspirin like- Reye Syndrome
NURSING CONSIDERATIONS Should not use in Sulfa allergy or Aspirin/Salicylate allergy Similar to Sulfamethaxozole (monitor CBC) a. Etanercept b. Adalimumab c. Infliximab d. Sulfasalazine e. Azathioprine/ Mercaptopurine f. Tacrolimus g. Cyclosporine h. Mycophenolate
d. Sulfasalazine
ADVERSE EFFECTS
Bone marrow Suppression
d. Sulfasalazine
e. Azathioprine/ Mercaptopurine
e. Azathioprine/ Mercaptopurine
USED TO TREAT Irritable Bowel Disease/ Ulcerative Colitis/Crohn’s Disease Rheumatoid Arthritis TRANSPLANTS d. Sulfasalazine e. Azathioprine/ Mercaptopurine
e. Azathioprine/ Mercaptopurine
Transplant Medications
LIFE
Lifelong therapy
Immunosuppressed (infection and malignancy risk)
Frequent monitoring of liver, kidneys , blood pressure and drug levels
Electrolyte abnormalities
ok
USED TO TREAT: ◦Rheumatoid Arthritis ◦Transplants ◦Ulcerative Colitis f. Tacrolimus g. Cyclosporine h. Mycophenolate
g. Cyclosporine
MECHANISM:
◦Inhibition of production and release of interleukin II and
inhibits interleukin II-induced activation of resting Tlymphocytes.
f. Tacrolimus
g. Cyclosporine
h. Mycophenolate
g. Cyclosporine
PROVIDER MUST BE EXPERIENCED IN IMMUNOSUPPRESSION AND TRANSPLANTS f. Tacrolimus g. Cyclosporine h. Mycophenolate
g. Cyclosporine
◦ IMMUNOSUPPRESSION/ MALIGNANCY RISK
f. Tacrolimus
g. Cyclosporine
h. Mycophenolate
g. Cyclosporine
◦ BIOAVAILABILITY (DO NOT SWITCH BRANDS/MANUFACTURERS)
f. Tacrolimus
g. Cyclosporine
h. Mycophenolate
g. Cyclosporine
◦ HYPERTENSION/ NEPHROTOXICITY
f. Tacrolimus
g. Cyclosporine
h. Mycophenolate
g. Cyclosporine
ADVERSE EFFECTS: ◦ Hirsutism ◦ Gingival Hyperplasia f. Tacrolimus g. Cyclosporine h. Mycophenolate
g. Cyclosporine
◦Just like with phenytoin, good oral hygiene
f. Tacrolimus
g. Cyclosporine
h. Mycophenolate
g. Cyclosporine
◦ We check trough levels ◦ Lots of drug interactions (Like NO GRAPEFRUIT JUICE!) f. Tacrolimus g. Cyclosporine h. Mycophenolate
g. Cyclosporine
No LIVE vaccines, do not use in active/recent Herpes/Chickenpox infection
f. Tacrolimus
g. Cyclosporine
h. Mycophenolate
g. Cyclosporine
USED TO TREAT: ◦Transplants ◦ Lots of off label auto-immune uses f. Tacrolimus g. Cyclosporine h. Mycophenolate
f. Tacrolimus
h. Mycophenolate
MECHANISM (inhibits T-lymphocyte activation) f. Tacrolimus g. Cyclosporine h. Mycophenolate
f. Tacrolimus
◦ 2 BOXED WARNINGS FROM THE FDA ◦ IMMUNOSUPPRESSION- INFECTION RISK ◦ MALIGNANCY RISK f. Tacrolimus g. Cyclosporine h. Mycophenolate
f. Tacrolimus
DO NOT USE STYROFOAM OR PAPER CUPS. USE GLASS OR PLASTIC
f. Tacrolimus
g. Cyclosporine
h. Mycophenolate
f. Tacrolimus
◦ FETAL TOXICITY
f. Tacrolimus
g. Cyclosporine
h. Mycophenolate
h. Mycophenolate
◦ 4 BOXED WARNINGS FROM THE FDA ◦ PROVIDER MUST BE EXPERIENCED IN IMMUNOSUPPRESSION AND TRANSPLANTS ◦ SERIOUS INFECTIONS/IMMUNOSUPPRESSION ◦ MALIGNANCY RISK ◦ FETAL TOXICITY f. Tacrolimus g. Cyclosporine h. Mycophenolate
h. Mycophenolate
CONSISTENCY- SAME TIME DAILY- CHECK TROUGH LEVELS! ( DON’T CHANGE BETWEEN MANUFACTURERS!)- NO GRAPEFRUIT JUICE
f. Tacrolimus
g. Cyclosporine
h. Mycophenolate
f. Tacrolimus
g. Cyclosporine
h. Mycophenolate
ADVERSE EFFECTS: ◦Hepatotoxicity ◦Nephrotoxicity ◦Electrolyte Abnormalities ◦Hypertension ◦Infections ◦Malignancies f. Tacrolimus g. Cyclosporine h. Mycophenolate
f. Tacrolimus
g. Cyclosporine
h. Mycophenolate
•LIFE
- Lifelong therapy
- Immunosuppressed (infection and malignancy risk)
- Frequent monitoring of liver, kidneys , blood pressure and drug levels
- Electrolyte abnormalities
f. Tacrolimus
g. Cyclosporine
h. Mycophenolate
f. Tacrolimus
g. Cyclosporine
h. Mycophenolate